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Background: Rubbing a topical NSAID (non steroidal anti-inflammatory drug) on the skin may increase local drug
permeation, affecting its distribution to the site of pain and inflammation. The present study evaluates this
hypothesis, by assessing in vitro the effect on skin permeation of applying diclofenac-dieythylamine 1.16% gel with
or without rubbing.
Methods: A single dose of 5 mg/cm2 diclofenac-diethylamine 1.16% gel was applied on excised human skin
mounted in Franz-type diffusion cells without or with rubbing for 45 s. Drug penetration into the skin layers was
determined after 1 h using the tape stripping technique. In vitro cutaneous permeation into the receptor fluid of
the diffusion chamber was measured up to 24 h. Skin electrical resistance was also recorded.
Results: Application of diclofenac-diethylamine 1.16% gel with rubbing resulted to a 5-fold higher flux of diclofenac
through the skin than when applied without rubbing at 8 h (P= 0.04). Skin rubbing for 45 s decreased by 2-fold
skin electrical resistance when compared to the standard application. Application of diclofenac-diethylamine 1.16%
gel with rubbing tended to result in higher accumulation in the stripped skin vs. the superficial skin layers when
applied without rubbing (P= 0.2).
Conclusion: These results suggest that rubbing may alter the superficial skin layer resulting in a transient faster
initial diffusion of topically applied diclofenac through the stratum corneum into the deeper skin layer of the
dermis to the tissue target.Background
Diclofenac is a non-steroidal anti-inflammatory drug
(NSAID) with known analgesic and anti-inflammatory
properties. Topical formulations of diclofenac have been
developed aiming to provide an effective analgesic and
anti-inflammatory effect, while reducing the risk for sys-
temic adverse effects that can be experienced with oral
NSAID formulations [1]. In its various formats (gel,
spray, patch etc.) diclofenac is widely used and is clinic-
ally proven to relieve pain, treat inflammation and re-
duce swelling in a number of acute and chronic
conditions affecting the joints and muscles [2,3] .
Topical diclofenac application produces a higher local
concentration of the drug, targeting the site of inflam-
mation and pain, where it preferentially distributes and
persists, achieving sufficiently high concentration to
exert local therapeutic activity, while systemic drug* Correspondence: nathalie.haslerguyen@novartis.com
Novartis Consumer Health, Nyon, Switzerland
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use, distribution, and reproduction in any medlevels are minimal [4]. Skin absorption is one of the
most critical factors for the effective distribution of the
drug to the site of inflammation and thus it can affect
the efficacy of the topical formulation. The route of drug
penetration across the stratum corneum, which is the
main rate limiting barrier to skin absorption [5], depends
on the physiochemical properties of the respective drug.
There is a common perception that the act of rubbing/
massaging a topical NSAID on the site of pain may pro-
vide an additional benefit to the patient. The high pla-
cebo effect observed in the clinical trials with topical
NSAIDs argues in favour of this perception [1]. The
mechanisms by which the act of rubbing may affect the
efficacy of the drug are not clear and they have not being
investigated extensively, but they may involve the activa-
tion of gating mechanisms and the desensitization of
local nerve endings. With this present study, we sought
to assess the hypothesis that rubbing a topical NSAID
onto the skin may result in increased penetration of the
drug through the skin layer and thus affecting theee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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sues. As the permeability properties of the stratum cor-
neum remain unchanged after removal from the body
and a good correlation has been observed between
in vivo and in vitro experiments with the same drug [6-
8], an in vitro diffusion through non viable human skin
has been considered a convenient experimental model to
evaluate the permeation characteristics of a topical drug
formulation. Thus, the present study compared the
in vitro skin permeation and distribution of 1.16%
diclofenac-diethylamine gel after application without or
with a rubbing for 45 s.
Methods
Product
Voltaren Emulgel (Novartis Consumer Health, Nyon
Switzerland) containing 1.16% diclofenac-diethylamine.
Product application
A single dose of 5 mg/cm2 was applied on excised human
skin mounted in Franz-type diffusion cells under non-
occlusive conditions. Rubbing was performed for 45 s
using the rounded end of a syringe piston while standard
application (considered as “without rubbing” under these
experimental conditions) of product onto skin lasted 5 s.
Skin donor
The ethical committee of the International Institute for
the Advancement of Medicine (IIAM; United States)
approved the use of human tissue in this study. Full
thickness human abdominal skin from 6 donors, which
was taken at autopsy, was provided cryopreserved by
IIAM. The skin was maintained frozen at −80°C. Prior
to use, the skin was thawed and the subcutaneous tissue
was carefully removed. The skin was dermatomed to
600 μm using a Wagner dermatome (model GB-231
Aesculap, Germany) to obtain split thickness tissue con-
stituted of the stratum corneum (10–20 μm), the epider-
mis (100 μm) and part of the dermis (1200 μm) [9,10].
Test of skin integrity
The permeation of tritiated water was evaluated to de-
termine the skin integrity as described by BronaughTable 1 Comparison of drug flux from gel
Flux (μg/cm2/h) Diclofenac 1.16% gel applied without rubbing (R)






Values represent mean from 11 replicates with standard error of mean (s.e.m), (* P<et al. [11]. Briefly, tritiated water (2.7 μCi/ml) was ap-
plied to the skin surface. After 30 min, the radiolabelled
water was removed from the skin with cotton-wool tips.
The amount of tritiated water (%) that permeated across
the skin was measured in the receptor phase (2 ml),
using a liquid scintillation counter. Less than 1% of the
applied dose of tritiated water permeated through the
skin. Skin with tritiated water permeation higher than
1% was excluded from the experiment. The experimental
procedure was performed with skin samples having simi-
lar tritiated water permeation values.Skin permeation
Skin permeation was measured using a static Franz dif-
fusion cell of 1.75 cm2 for each skin sample exposed to
5 mg/cm2 of the product in accordance to the test
guideline OECD 428 [12].
Thawed human dermatomed (600 μm) skin samples
were mounted horizontally on the Franz cells with the
dermis facing down. The Franz diffusion cells were con-
nected to a circulating water bath at 37°C, which yielded
a tissue temperature of 32°C, comparable to the physio-
logical temperature of the skin surface. The diffusion
area was 1.75 cm2 and the receptor phase of PBS pH 7.4
(phosphate buffered saline; 7.58 g/L Na2HPO4, 1.62 g/L
NaH2PO4 and 4.4 g/L NaCl) contained within each dif-
fusion cell (approximately 8 ml) was mixed using a mag-
netic stirring device to ensure appropriate
homogenization of the released drug in the acceptor
phase throughout the experiment. Samples of the recep-
tor phase were collected and analysed to determine
diclofenac concentration at baseline, 2 h, 4 h, 8 h and
24 h (Table 1).Cutaneous distribution
Cutaneous distribution was determined by measuring
the amount of drug residing in the various skin layers.
One hour (1 h) after the application of 5 mg/cm2, skin
samples were washed off with soapy water and cotton-
wool tips. The top layer of the stratum corneum was
removed with adhesive tape (3 M Scotch n° 550) and
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Figure 1 Comparison of diclofenac flux after application of
diclofenac-diethylamine 1.16% gel applied with or without
rubbing. Values represent mean from 11 replicates with mean
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Figure 2 Comparison of skin electrical resistance with or
without rubbing. Values represent mean from at least 5 replicates
with mean standard errors (*** P< 0.001).
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tape strips.
Following collection of all strips, the first and the sec-
ond strips were put into separate vials containing 10 ml
of water. Strips 3 up to 7 were pooled in the same vial
containing 20 ml of water. The remaining stripped skin
was minced and placed into a vial containing 15 ml PBS
pH 7.4. Mixtures were stirred overnight to ensure ad-
equate extraction of the drug from the tape and the
skin.
Sample analysis
Diclofenac content in the various samples was measured
by ultra high performance liquid chromatography
(Waters Acquity) on a Waters Aquity UPLCWBEH C18
1.7 μm (2.1 × 50 mm) phase column at 35°C using a flow
rate of 0.5 ml/min of the mobile phase of a mixture of
purified water with 1% acetic acid and acetonitrile
4.2:5.8 (v:v) with UV detection at 275 nm. The sample
was directly injected at a volume of 10 μl. The retention
time of diclofenac was 3.2 min. The area under the peak
was used to calculate the concentration of diclofenac
using external standards that showed a linearity over the
concentration range of 0.03 to 1 μg/ml.
Measurement of tissue resistance
Discs of excised human abdominal split thickness skin
of 600 μm were put on Transwell insert without mem-
brane. The diffusion area was 1.1 cm2 and the receiver
phase consisted of PBS pH 7.4 at 32°C (1.5 ml) with a
donor phase of 0.5 ml PBS pH 7.4 at 32°C. Skin resist-
ance was measured before rubbing. After the pretreat-
ment 0.5 ml of donor phase preheated at 32°C was
added. After 5 min up to 2 h the tissue resistance was
determined with EVOMX (World Precision Instruments,
Sarasota, FL). Ratio of the resistance before and after the
rubbing were calculated and compared to the same non-
rubbed skin.
Statistical analysis
Unpaired Student t-test were performed to define a P
value between applications with or without rubbing. A P
value of less than 0.05 was considered statistically
significant.
Results
Diclofenac flux after application of diclofenac-
diethylamine 1.16% gel without and with rubbing for
45 s is shown in Figure 1 and Table 1. When the product
was applied on the skin followed by rubbing the flux was
5-fold higher at 8 h than when applied without rubbing
(P= 0.04). This difference leveled off at the end of the
experiment at 24 h.To further evaluate the effect of rubbing on the skin
barrier, the trancutaneous electrical resistance was mea-
sured (Figure 2). The transcutaneous electrical resistance
values at 5 min and 2 h were similar and, thus, only the
2 h data are shown in Figure 2. The electrical resistance
before rubbing was between 6 kΩ/cm2 – 20 kΩ/cm2
and after rubbing between 4 kΩ/cm2 – 13 kΩ/cm2.
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to be 2-fold lower after application of the product with
rubbing than without (P< 0.001).
Finally, application of diclofenac-diethylamine 1.16%
gel with a 45 s rubbing tended to result in higher accu-
mulation in the stripped skin (P= 0.2; Figure 3). In con-
trast, it appears that when diclofenac-diethylamine
1.16% gel was applied without rubbing it tended to re-
main in the superficial skin layers, as represented by
strip 1 in Figure 3 (P= 0.2).Discussion
This in vitro study demonstrated that rubbing
diclofenac-diethylamine 1.16% gel for 45 s resulted in a
5-fold higher flux of diclofenac through the skin when
compared to application without rubbing. This effect
was observed at 8 h post application, while concentra-
tion of the active penetrating through the skin reached a
plateau after 24 h. This indicates that the act of rubbing
may affect the speed of the transcutaneous penetration
of the drug through the skin, which may result in transi-
ent higher availability of the active in the subcutaneous
muscle and joint tissues.
A consistent trend was also observed between the kin-
etics of diclofenac absorption through the skin and its
electrical resistance when the product was applied with
rubbing. Such application, in addition to increasing
diclofenac’s flux, also resulted to a 2-fold reduction of
the skin’s electrical resistance. Furthermore, application
with rubbing resulted in numerically higher concentra-
tion of diclofenac in stripped skin, corresponding to the
deeper skin layer.
These findings suggest that the act of rubbing may
transiently affect skin’s lipid structure, resulting in a



























Figure 3 Comparison of diclofenac’s concentration in individual
tape strips (1,2,3), in the pooled strips and in the remaining
stripped skin after application of diclofenac-diethylamine
1.16% gel with or without rubbing. Values represent mean from
11 replicates with mean standard errors.the rubbing did not seem to disrupt the skin barrier. In-
deed, the electrical resistance of the skin explants used
in this in vitro study, was constantly higher than 3.9 kΩ/
cm2 which is the cut-off value for considering the skin
intact [13]. Further experiments may be needed to evalu-
ate the effect of rubbing on the skin hydration, as per-
meability is known to depend on the water content of
the stratum corneum [14]. It is believed that hydration
induces stratum corneum swelling and fluidization of
lipid bilayers leading to a reduction of the electrical re-
sistance [14], which was observed in this study.
Measurement of in vitro permeation across the split
thickness of human skin allows the evaluation of the
passive diffusion of the molecule into and across the
skin to a solute reservoir, which simulates the capillaries
of the dermis. As permeability properties of the stratum
corneum remain unchanged in non-viable human skin
the results of this study may be extrapolated to in-use
condition. Several factors can influence a drug skin per-
meation, such as its release from the formulation, its
penetration into the stratum corneum layers (10–20 μm)
and its diffusion through the stratum corneum into the
various epidermis layers (100 μm) and the dermis
(1200 μm). The in vitro system used in this study pro-
vided an insight on the kinetics of diclofenac through
the skin and on the role that the act rubbing may play in
altering the skin layer parameters, to allow the drug to
reach the subcutaneous tissues faster, increasing their
initial exposure to it. This may potentially affect the effi-
cacy of the drug and may partially explain the positive
effect of rubbing/massaging observed in the clinical set-
ting with the use of topical NSAIDs. Further studies,
and particularly prospective human clinical trials, will be
needed to further evaluate the findings demonstrated
with this in vitro model.
Conclusions
Application of diclofenac-diethylamine 1.16% gel with
rubbing for 45 s increased diclofenac flux through the
skin up to 5-fold at 8 h. However, at 24 h, the amount of
diclofenac penetrating through the skin after standard
application or application with rubbing was not differ-
ent. This indicates that the act of rubbing may accelerate
the speed of the drug transcutaneous delivery without
altering the integrity of the skin.
This in vitro study demonstrated for the first time that
the flux of a molecule across the skin can be modified
by a mechanical act. In general gel formulations are ap-
plied by rubbing, but this study demonstrated that the
duration of this action may play an important role and
prolonging it may result to a higher flux of the drug
through this skin barrier. Since the properties of the
stratum corneum remain unchanged when it is removed
from the body [6-8] these in vitro observations may
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studies are required to confirm this hypothesis.
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